Non-invasive prenatal testing (NIPT)
Panorama is a blood-based genetic, prenatal screening test of the pregnant mom that screens for common chromosomal conditions that affect a baby’s health. Panorama uses unique SNP*-based technology to deliver the most accurate non-invasive prenatal testing on the market.
Panorama can be performed as early as nine weeks gestation. Most results will be returned to your doctor within 5-7 calendar days.
*SNP, single nucleotide polymorphism
Panorama has now been used in more than three million pregnancies
From Natera’s beginning, one of our core values has been recognizing that there is a patient behind every sample. We thank you for your support, and for the trust that you have placed in Panorama to make it the #1 NIPT for your patients.
Validated in SMART, the largest prospective NIPT study1-3
SMART study key findings regarding Panorama AI
Decreased “no-call” rates without sacrificing accuracy1
SMART demonstrated equivalent performance of Panorama AI with previous Panorama version while “no-call” rates were significantly decreased
Improved 22q11.2 deletion detection2
Panorama AI was shown to have improved detection of 22q11.2 deletions including small, nested deletions
“No-calls” can inform pregnancy management3
Pregnancies with “no-call” results had a high correlation with late-term adverse pregnancy outcomes
Why choose Panorama for fetal genetic testing?
Clinical advantages of genetic testing for pregnancy:
- Panorama detects conditions that other tests cannot, including molar pregnancy, triploidy and vanishing twin.4
- Panorama screens for Down syndrome with an accuracy rate greater than 99%.1,5-7
- Panorama is the only test that differentiates between maternal and fetal DNA, which helps avoid false positives and false negatives.1,5-9
- Panorama is the only NIPT that can assess zygosity, individual fetal sex, and individual fetal fraction* in twin pregnancies.10
- Panorama has the highest sensitivity for 22q11.2 deletion syndrome, a common and potentially severe microdeletion that impacts pregnancies equally regardless of maternal age.2
- Panorama can be performed for singleton, twin, egg donor, and surrogate pregnancies.9
*For dizygotic twins only
Panorama’s SNP-enabled capabilities make every result matter
Vanishing twin detection4
Recognized by the American College of Obstetricians and Gynecologist (ACOG) as a major cause of NIPT false positives8
Maternal X mosaicism detection11
As women age, mosaicism for a missing X chromosome becomes more common, and is another ACOG-recognized major cause of error in NIPT8
As stated in ACOG practice bulletin 226, SNP-based NIPT (Panorama) is the only non-invasive method that can identify triploidy8
Clinically validated differentiation for twin pregnancies
Recognized by the International Society for Prenatal Diagnosis (ISPD) as an important element in evaluating NIPT results for twins12
Individual fetal fraction for dizygotic twins10,13
An important metric necessary to interpret the reliability of NIPT results, ACOG recognizes that, without this measurement, aneuploidy could go undetected if the affected twin has low fetal fraction8
Individual fetal sex10
With zero fetal sex errors in published validation studies for both singletons and twins, patients and clinicians can have confidence in Panorama results5-7,10
Other conditions screened9
- Trisomy 21
- Trisomy 18
- Trisomy 13
- Sex chromosome trisomies (reported when seen)*
- 22q11.2 deletion syndrome (optional)*
*Identical twins only
Is Panorama right for you?
We’re here to help you find out
1Dar et al. Multicenter prospective study of SNP-based cfDNA screening for aneuploidy with genetic confirmation in 18,497 pregnancies. Society of Maternal-Fetal Medicine, SMFM. Virtual Meeting. Oral Presentation. Jan 25-30, 2021.
2Dar et al. Multicenter prospective study of SNP-based cfDNA for 22q11.2 deletion in 18,290 pregnancies with genetic confirmation. Society of Maternal-Fetal Medicine, SMFM. Virtual Meeting. Oral Presentation. Jan 25-30, 2021.
3Norton et al. Perinatal and genetic outcomes associated with no call cfDNA results in 18,497 pregnancies. Society of Maternal-Fetal Medicine, SMFM. Virtual Meeting. Oral Presentation. Jan 25-30, 2021.
4Nicolaides et al. Fetal Diagn Ther. 2014;35(3):212-7.
5Pergament et al. Obstet Gynecol. 2014 Aug; 124(2 Pt 1):210-8.
6Nicolaides et al. Prenat Diagn. 2013 June; 33(6):575-9.
7Ryan et al. Fetal Diagn Ther. 2016;40(3):219-223.
8ACOG Practice Bulletin 226. Obstet Gynecol. 2020 Oct;136(4):859-867.
9Natera internal data on file.
10Norwitz et al. J Clin Med. 2019 Jun; 8:937.
11Martin KA et al. Am J Obstet Gynecol MFM. 2020;2:100152.
12Palomaki GE, et al. Prenat Diagn. 2020 Oct 5. doi: 10.1002/pd.5832. [Epub ahead of print].
13Hedriana H et al. Prenat Diagn. 2020 Jan;40(2):179-184.
14Society for Maternal-Fetal Medicine, Clinical guideline: Twin-twin transfusion syndrome, Jan 2013.
15American College of Obstetricians and Gynecologists and Society for Maternal-Fetal Medicine, practice bulletin #169, Oct 2016.
16Oldenburg et al. Ultrasound Obstet Gynecol. 2012 Jan;39(1); 39: 69–74.
17Chasen, Chervenak (2017). Twin pregnancy: Prenatal issues. In T. Post (Ed.), UpToDate. Waltham, Mass.: UpToDate. Retrieved from www.uptodate.com
18Cunningham et al. Williams Obstetrics. 24th edition. New York: McGraw-Hill Education, 2014.